A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 48
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : HK
Long Form : hyperkalemia
No. Year Title Co-occurring Abbreviation
2021 A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure Using a Large Administrative Claims Database. AUROC, CKD, DM, HTN
2021 Current Management of Hyperkalemia in Non-Dialysis CKD: Longitudinal Study of Patients Receiving Stable Nephrology Care. sK
2021 Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study. HF, RAASi
2021 Healthcare utilization and expenditures associated with hyperkalemia management: a retrospective study of Medicare Advantage patients. CI, ED, OR
2021 Prevalence and clinical correlates of hyperkalemia in stable kidney transplant recipients. CNI, eGFR, KTRs
2021 The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review. CV, HD
2020 A Model to Predict Risk of Hyperkalemia in Patients with Chronic Kidney Disease Using a Large Administrative Claims Database. AUC, AUROC, BY, CKD, PY, RAASi
2020 Cost-analysis of persistent hyperkalaemia in non-dialysis chronic kidney disease patients under nephrology care in Italy. CKD, ESRD
2020 Cost-Effectiveness Analysis of Patiromer in Combination with Renin-Angiotensin-Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden. CKD, ICER, QALYs, RAASi, SEK
10  2020 Effect of patiromer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials. AEs, HF, SE
11  2020 Frequency and clinical impact of hyperkalaemia within a large, modern, real-world heart failure population. HF, LVEF, MACE, RAASi
12  2020 Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization. HRU, RAASi, SPS
13  2020 Incidence and Clinical Significance of Hyperkalemia Following Heart Transplantation. ---
14  2020 Metabolic acidosis and hyperkalemia differentially regulate cation HCN3 channel in the rat nephron. BBM, CMA, HCN
15  2020 Pharmacodynamic effects of the K+ binder patiromer in a novel chronic hyperkalemia model in spontaneously hypertensive rats. SHR
16  2020 Prevalence and correlates of hyperkalemia in a renal nutrition clinic. CKD
17  2020 Real-world management of hyperkalemia with patiromer among United States Veterans. CKD, HF
18  2020 Risk factors associated with the incidence and recurrence of hyperkalaemia in patients with cardiorenal conditions. CKD, CPRD, eGFR, HES, RAASi, RHTN
19  2020 Serum Potassium As A Predictor Of Adverse Clinical Outcomes In Patients With Increasing Comorbidity Burden. ACM, CCI, HF, MACE
20  2020 The burden of hyperkalemia in Germany - a real world evidence study assessing the treatment and costs of hyperkalemia. ---
21  2020 Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. ACEi, ARB, HF, MRA, RAASi
22  2019 Acute heart failure and adverse events associated with the presence of renal dysfunction and hyperkalaemia. EAHFE- renal dysfunction and hyperkalaemia. AHF, HR, RD, RD-Hk, RD-NoHk
23  2019 Association of hyperkalemia with clinical outcomes in advanced chronic kidney disease. CKD, eGFR
24  2019 Associations between serum potassium and adverse clinical outcomes: A systematic literature review. CKD, HF, MACE, RAASi
25  2019 Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England. HRU
26  2019 Healthcare resource utilisation and cost associated with elevated potassium levels: a Danish population-based cohort study. CKD, HF
27  2019 Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. CKD, RAASis
28  2019 Optimally managing hyperkalemia in patients with cardiorenal syndrome. HF, HFrEF, RAASi
29  2019 Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia. CKD, RAASis
30  2019 Rapid correction of hyperkalemia is associated with reduced mortality in ED patients. ED, EMR
31  2019 Renal potassium handling in chronic kidney disease: Differences between patients with or wihtout hyperkalemia. CKD, FEK, NK
32  2019 [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease]. CKD, CV, HF, ID, RAASi
33  2018 Chronic Hyperkalemia in Cardiorenal Patients: Risk Factors, Diagnosis, and New Treatment Options. CKD, HF
34  2018 Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ACEi, ARB, CKD, EF, HF
35  2018 The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia. AEs, CKD, DDI, HF, RAASi
36  2017 Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure. CKD, HF, RAASi
37  2017 Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure. CKD, HF, RAASi
38  2017 Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study. CI, CKD, eGFR, PR
39  2017 Hyperkalaemia prevalence, recurrence and management in chronic haemodialysis: a prospective multicentre French regional registry 2-year survey. SPS
40  2014 Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study. HF, WRF
41  2014 Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy. AA, BUN, LDH, PRRT
42  2013 Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). WRF
43  2006 Effects of dofetilide and EGIS-7229, an antiarrhythmic agent possessing class III, IV, and IB activities, on myocardial refractoriness in hyperkalemia, hypokalemia, and during beta-adrenergic activation in the rabbit papillary muscle in vitro. ERP, NK
44  1991 Insulin effects on glucose and potassium metabolism in vivo: evidence for selective insulin resistance in humans. AN
45  1989 Antiarrhythmic effects of selective beta 1- and beta 2- and nonselective beta-adrenoceptor blockade in normokalaemic and dietary-induced hypokalaemic rats. EPI, i.v, NE, NK
46  1987 Effects of diet-induced hypokalaemia on the antiarrhythmic and electrophysiological actions of prolonged oral treatment with either amiodarone or disopyramide in the anaesthetised rat. NK
47  1984 The cyclic AMP system in the inner medullary collecting duct of the potassium-depleted rat. AC, AVP, IMCT
48  1983 Studies on the effects of hyperkalemia on serum and myocardial digoxin concentration in dogs. DX, NK